SCHEMBL5162449

SCHEMBL5162449

O=C(O)C(Cc1ccc(-c2ccccc2)o1)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.54
HSD17B10 Q99714 3/20 0.54
MAPT P10636 3/20 0.54
PKM P14618 3/20 0.54
POLB P06746 2/20 0.54
HTT P42858 2/20 0.54
TDP1 Q9NUW8 1/20 0.54
ALOX5 P09917 2/20 0.49
CYP2C19 P33261 3/20 0.49
CYP2E1 P05181 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2A6 P11509 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2B6 P20813 1/20 0.49
HRH1 P35367 1/20 0.45
KDM4E B2RXH2 3/20 0.43
HPGD P15428 3/20 0.42
PPARG P37231 2/20 0.42
PPARA Q07869 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5162353 0.87 ALDH1A1 (0.54) ALDH1A1HSD17B10MAPTPKMPOLB
SCHEMBL11860557 0.81 ALDH1A1 (0.57) ALDH1A1HSD17B10MAPTPKMPOLB
SCHEMBL11624978 0.73 HRH1 (0.58) ALDH1A1HSD17B10MAPTPKMPOLB
SCHEMBL9208149 0.73 ALDH1A1 (0.69) ALDH1A1HSD17B10MAPTPKMPOLB
SCHEMBL13541830 0.73 HRH1 (0.62) ALDH1A1HSD17B10MAPTPKMPOLB
SCHEMBL5162678 0.72 HPGD (0.47) ALDH1A1HSD17B10MAPTPKMPOLB
SCHEMBL5869827 0.72 HRH1 (0.49) ALDH1A1HSD17B10MAPTPKMPOLB
SCHEMBL5869822 0.72 HRH1 (0.49) ALDH1A1HSD17B10MAPTPKMPOLB
SCHEMBL6924748 0.72 HRH1 (0.49) ALDH1A1HSD17B10MAPTPKMPOLB
SCHEMBL5869815 0.72 HRH1 (0.49) ALDH1A1HSD17B10MAPTPKMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1748984-A1 PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS Pfizer Products Inc. (US) 2007-02-07 EP disclosed
WO-2005110987-A1 PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS PFIZER PRODUCTS INC. (US) 2005-11-24 WO disclosed
US-20050256164-A1 NK1 and NK3 antagonists PFIZER INC 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256164-A1 NK1 and NK3 antagonists TAC3, TACR1, TACR2 ALDH1A1 3567/4885HSD17B10 4616/4885MAPT 2851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.